Bausch Health Companies Inc. filings document regulatory disclosures for a global diversified pharmaceutical company incorporated in British Columbia. The record includes Form 8-K reports for quarterly and annual operating results, Regulation FD updates, clinical-program disclosures, material agreements, debt exchanges and credit-agreement refinancing involving Bausch Health and its subsidiaries, including Bausch + Lomb.
Proxy materials describe annual meeting matters, director elections, auditor approval, executive compensation votes and governance procedures. Other current reports address compensatory arrangements, including performance share unit settlement terms, and capital-structure disclosures tied to senior secured notes, guarantees, collateral arrangements and refinancing transactions.
Bausch Health Companies Inc. filed a current report to share that it has issued a press release about the results of its global Phase 3 RED-C clinical program. This study evaluated amorphous-rifaximin solid soluble dispersion in adults with liver cirrhosis for the primary prevention of hepatic encephalopathy.
The company furnished the press release as Exhibit 99.1 and stated that this information is being provided under Regulation FD, meaning it is intended as a broad, fair disclosure to the market. The furnished material is not considered "filed" for liability purposes under the Exchange Act or automatically incorporated into other securities filings unless specifically referenced.
Bausch Health Companies Inc. filed a report ahead of its participation in the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company plans to present at approximately 3:45 p.m. PT (6:45 p.m. ET), where management will share strategic and business updates with investors.
During this presentation, Bausch Health’s management also expects to reaffirm its full-year 2025 guidance at the higher end of the range for Bausch Health excluding Bausch + Lomb Corporation, as previously provided with its third quarter 2025 results. The presentation will be available via live audio webcast, with the materials and a replay posted on the company’s Investor Relations website.
Bausch Health Companies Inc. reports that its subsidiary Bausch + Lomb Corporation has refinanced its term loans by entering into a Fourth Amendment to its Credit and Guaranty Agreement. The amendment establishes a new $2,802,125,000 tranche of term loans maturing on January 15, 2031, with proceeds used to refinance existing term B loans due 2031 and 2028. The new loans amortize at 1.00% per annum, with the first installment due June 30, 2026. The applicable margins are 3.75% per annum for loans tied to term SOFR and 2.75% per annum for loans tied to the alternate base rate, representing reductions of 0.50% and 0.25% per annum compared to the prior tranches. The structure effectively extends the maturity of the earlier 2028 term loans to 2031.
Bausch Health Companies Inc. director John Paulson reported equity-based board compensation and his holdings in a Form 4 filing. On 12/31/2025, he acquired 8,992 restricted share units at a price of $0, issued in lieu of cash compensation for his service on the board for the quarter ending December 31, 2025. Each unit represents a contingent right to receive one common share of Bausch Health with no par value.
Following this transaction, Paulson beneficially owned 360,120 common shares directly. In addition, 73,255,869 common shares were reported as indirectly owned through investment funds managed by Paulson Capital Inc., where he is the controlling person. The filing notes that Paulson may be deemed an indirect beneficial owner of these fund-held securities and that he disclaims beneficial ownership except to the extent of any pecuniary interest.
Bausch Health Companies Inc. director reported receiving an equity-based compensation award for board service. On December 31, 2025, the director acquired 4,586 restricted share units, each representing a contingent right to receive one common share of the company with no par value. These units were issued in lieu of cash compensation for serving on the board for the quarter ending December 31, 2025. Following this award, the director beneficially owned 38,408 common shares on a direct basis.
Bausch Health Companies Inc. reported that one of its directors received equity compensation for board service for the quarter ending December 31, 2025. The director was granted 989 restricted share units, each representing a contingent right to receive one common share with no par value, issued in lieu of cash compensation. After this grant, the reporting person beneficially owned 266,441 common shares, held directly.
Bausch Health Companies Inc. completed previously announced exchange offers, issuing $1.6 billion aggregate principal amount of new 10.00% Senior Secured Notes due 2032 through its indirect wholly owned subsidiary 1261229 B.C. Ltd. These new notes were exchanged for outstanding 4.875% and 11.00% Senior Secured Notes due 2028 under terms described in a confidential exchange offer memorandum.
The new 2032 notes were issued under an existing indenture structure and form a single series with $4.4 billion principal amount of the Issuer’s existing 10.00% Senior Secured Notes due 2032, sharing the same terms except for interest accrual, consideration and temporary securities identifiers. In connection with this issuance, an additional 26,495,472 common shares of Bausch + Lomb Corporation were pledged, bringing the Issuer’s pledged stake to 211,963,893 shares, representing approximately 60% of Bausch + Lomb’s outstanding common shares as of the settlement date. The existing and new notes are secured by a first priority lien on substantially all assets of the Issuer and other guarantors, including this equity stake.
Bausch Health Companies Inc. reported the final results and expiration of its previously announced debt exchange offers. The company had offered holders of its outstanding 4.875% and 11.00% Senior Secured Notes due 2028 the option to exchange into up to $1.6 billion aggregate principal amount of new 10.00% Senior Secured Notes due 2032, to be issued by its indirect wholly owned subsidiary 1261229 B.C. Ltd. These exchanges were conducted under the terms of a confidential exchange offer memorandum dated November 24, 2025, and expired at 5:00 p.m. New York City time on December 23, 2025. Additional details on the final exchange results are provided in a press release attached as an exhibit.
Bausch Health Companies Inc. reported that its subsidiary Bausch + Lomb Corporation has allocated a new $2,802,125,000 tranche of term B loans, called the Replacement Term Loans, to refinance its existing term B loans due 2031 and 2028. The new loans are expected to carry an applicable margin of 3.75% per annum for loans tied to term SOFR and 2.75% per annum for loans tied to the alternate base rate.
The margins represent a 0.50% per annum reduction versus the existing Third Amendment Term Loans and a 0.25% per annum reduction versus the First Incremental Term Loans. The Replacement Term Loans will mature on January 15, 2031, maintaining the current 2031 maturity while extending the former 2028 maturity. The transactions are anticipated to close in the first quarter of 2026, though completion on these terms is not assured.
Bausch Health Companies Inc. reported the early results of its previously announced debt exchange offers. The company is offering to exchange its outstanding 4.875% Senior Secured Notes due 2028 and 11.00% Senior Secured Notes due 2028 for up to $1.6 billion aggregate principal amount of new 10.00% Senior Secured Notes due 2032, to be issued by indirect wholly owned subsidiary 1261229 B.C. Ltd., under the terms described in a confidential exchange offer memorandum dated November 24, 2025. The update covers early participation results as of 5:00 p.m. New York City time on December 8, 2025, as detailed in an accompanying press release. The company also notes that the new notes will not be registered under U.S. or Canadian public offering rules and may only be offered or sold under applicable exemptions.